Project Grant HT9425261E047
Award Date 7/1/26
Completion Date 6/30/29
Dollars Obligated $560K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
- Federal Grant Award Summary The University of Texas MD Anderson Cancer Center received a $414,472 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) effective September 1, 2025, through August 31, 2028. The award supports research targeting neuronal mimicry in SMARCB1-deficient renal medullary carcinoma (RMC) treatment. This three-year initiative delivers translational research and therapeutic development services...
- Federal Project Grant Award Summary The University of Texas MD Anderson Cancer Center received a $893,525 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) effective September 1, 2025, through August 31, 2028. The award funds research titled "Targeting Neuronal Mimicry in SMARCB1-Deficient Renal Medullary Carcinoma Treatment," which investigates novel therapeutic approaches to address renal medullary...
- Federal Grant Award Summary The University of Texas MD Anderson Cancer Center received a $489,767 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) effective October 1, 2025, through September 30, 2028. The award supports research titled "Building T-Cell Products in NF1-Associated MPNST Through Antigen Discovery and Epigenome Targeting," which addresses the development of therapeutic T-cell immunotherapy...
- Federal Grant Award Summary The University of Texas MD Anderson Cancer Center received a $1.35 million Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) for the three-year period from October 1, 2025, through September 30, 2028. The award funds research focused on building T-cell products for neurofibromatosis type 1 (NF1)-associated malignant peripheral nerve sheath tumors (MPNST) through antigen discovery and...
- Federal Project Grant Award Summary The University of Texas MD Anderson Cancer Center received a $817,496 project grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) effective September 1, 2025, through August 31, 2028. The award funds research to investigate the PRMT3-IGF2BP1 axis-mediated epitranscriptomic reprogramming as a novel therapeutic strategy to overcome immunotherapy resistance in clear cell renal cell carcinoma...
- Federal Project Grant Award Summary The University of Texas MD Anderson Cancer Center received a $5.47M Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective September 1, 2025, through August 31, 2029. The award funds research aimed at targeting ganglioside GD2 to overcome chemotherapy resistance in triple-negative breast cancer. This research initiative represents translational and clinical investigation...
- Federal Grant Award Summary The University of Texas MD Anderson Cancer Center received a $1.40M project grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) effective June 1, 2026, through May 31, 2029. The award supports research titled "Combined Pan and Precision Targeting in Extrachromosomal DNA-Positive Gastric Cancer," which investigates innovative therapeutic approaches for gastric cancer cases with...
- Federal Project Grant Award Summary The University of Texas MD Anderson Cancer Center received a $1,431,215 project grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) awarded October 1, 2025, with a completion date of September 30, 2028. The award funds research focused on building T-cell products for neurofibromatosis type 1 (NF1)-associated malignant peripheral nerve sheath tumors (MPNST) through antigen discovery and...
- Federal Project Grant Award Summary The University of Texas MD Anderson Cancer Center received a $560K project grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) beginning September 1, 2026, with completion targeted for August 31, 2028. The award funds research on modulating hypoxia-activated stromal programs to potentiate chimeric antigen receptor T (CAR-T) cell therapy in kidney cancer. This translational oncology research...
- Federal Project Grant Award Summary The University of Texas MD Anderson Cancer Center received a $349,976 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) for the period July 1, 2026 through June 30, 2028. The award funds research focused on intercepting omental metastasis of ovarian cancer through targeting a mitochondrial redox-interleukin-10 (IL-10) axis in the immune microenvironment. This research initiative...